JBCHEPHARM JB Chemicals & Pharmaceuticals Q2 FY25 results (Jul–Sep 2024) and concall
J B Chemicals delivered a strong Q2 FY25, crossing the ₹1,000 crore revenue milestone driven by robust 22% growth in the domestic market. While the CDMO segment faced temporary supply chain headwinds that deferred $2 million in sales to Q3, management remains confident in its long-term $100 million revenue target for the segment. The company continues to maintain industry-leading margins of ~28% while aggressively scaling its acquired chronic and ophthalmology portfolios.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY25 | Q2 FY25 |
|---|---|---|
| Revenue | 952 | 956 |
| EBITDA | 273 | 268 |
| Net profit | 173 | 173 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
